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Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) 
Guidelines 
Abstract 
This paper provides examples of defining estimands in real-world scenarios following ICH E9(R1) 
guidelines. Detailed discussions on choosing the estimands and estimators can be found in our 
companion papers1,2. Three scenarios of increasing complexity are illustrated. The first example is 
a proof-of-concept trial in major depressive disorder where the estimand is chosen to support the 
sponsor decision on whether to continue development. The second and third examples are 
confirmatory trials in severe asthma and rheumatoid arthritis respectively. We discuss the 
intercurrent events expected during each trial and how they can be handled so as to be consistent 
with the study objectives. The estimands discussed in these examples are not the only acceptable 
choices for their respective scenarios. The intent is to illustrate the key concepts rather than focus 
on specific choices. Emphasis is placed on following a study development process where 
estimands link the study objectives with data collection and analysis in a coherent manner, thereby 
avoiding disconnect between objectives, estimands, and analyses.  
Key words: Estimands, Clinical Trials, Intercurrent events 
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1. Introduction 
This paper provides detailed examples of estimand definitions in several clinical trial settings to 
facilitate practical implementation of guidelines outlined in the ICH E9(R1) draft addendum on 
“Estimands and Sensitivity Analysis in Clinical Trials”3. This paper follows the framework 
introduced in ICH E9(R1) that is further discussed in our companion papers on estimands1 and 
estimators2.  
Three progressively more complex examples are illustrated in this paper. The first is a proof-of-
concept (PoC) trial in major depressive disorder (MDD), where the key decision maker is the 
sponsor who must decide whether the drug has sufficient potential benefit to continue in 
development. The second example is a confirmatory trial of an add-on maintenance treatment for 
patients with severe asthma. The third example is a confirmatory trial in rheumatoid arthritis (RA). 
The last two are complex examples where estimands need to address the interests of multiple stake-
holders, e.g., sponsors, regulators, patients, prescribing physicians, and payers, although our focus 
is on estimands for regulatory decision-making.  
In most studies (including our examples) a variety of post-randomization events that mark a change 
in the course of treatment, e.g., initiation of rescue therapy or premature discontinuation of the 
randomized treatment, can be anticipated. Such events may influence the estimation and 
interpretation of treatment effects. These events are referred to as intercurrent events (ICEs) in 
ICH E9(R1), and the guideline stipulates that handling of these events needs to be described as 
part of the estimand definition. The examples in this paper describe the strategies that can be 
chosen for the ICEs in the corresponding clinical contexts. For each example, we provide full 
specifications of estimands following a template of the estimand definition suggested in ICH 
E9(R1). 
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The estimands described in these examples are not the only acceptable choices for the respective 
clinical settings. Other estimands may be of interest to some decision-makers. This paper intends 
to illustrate the process and key concepts rather than focus on specific choices. More details about 
the assumptions behind and implications of different strategies for dealing with ICEs can be found 
in the companion paper on estimands1. For each example we also briefly mention which analysis 
methods, i.e., estimators, can be used so that they are well aligned with the defined estimands. It 
should be noted that for a given estimand several suitable estimators may exist (e.g., for estimating 
a difference between population means); justification of the specific choices of analysis methods 
is beyond the scope of this manuscript and more details about estimation methods can be found in 
the second companion paper2. 
Section 2 provides a brief overview of the estimand definition elements and strategies for the ICEs 
outlined in ICH E9(R1)3, as well a trial design process1 wherein the estimand defines the scientific 
question of interest and links the study objectives with data collection and analysis in a coherent 
manner. Section 3 presents the first example, MDD, and provides a high-level view of the key 
considerations in a PoC study that drive the choice of the estimand in this context. Sections 4 and 
5 are devoted to the examples in severe asthma and rheumatoid arthritis, respectively. Each of 
these examples begins with a description of the clinical context so that ICEs, likely to occur in 
these contexts, can be identified. We then briefly summarize one historical confirmatory clinical 
trial for the corresponding indication. The estimands were not explicitly defined in publicly 
available sources for these trials, so we reconstruct the implied primary estimands based on the 
description of the trial designs and primary analyses. This is not the process that should be followed 
at the time of a prospective trial design; we use it mainly to fix ideas and provide some background 
about the therapeutic areas and as an illustration of how some approaches typically utilized in these 
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therapeutic areas can be expressed in a formal estimand definition. We provide a discussion of 
how the primary estimands used in these historical trials focus on the needs of the intended 
decision-makers. Subsequently, we suggest some alternative estimands that may also be 
appropriate in the same clinical context but would stem from a different objective.  
2. Overview of estimand definition elements and trial design process 
This section briefly summarizes the key elements required for an estimand definition. The reader 
is referred to ICH E9(R1)3 and the companion paper1 for an in-depth introduction.   
An estimand describes the quantity to be estimated to address a specific study objective. ICH 
E9(R1) outlined four elements that together comprise the estimand definition: 
A. the population, i.e., the patients targeted by the scientific question; 
B. the variable (or endpoint) to be measured for each patient to address the scientific 
question; 
C. how to account for ICEs to reflect the scientific question of interest; 
D. the population-level summary for the variable which provides a basis for a comparison 
between treatment conditions. 
Elements A, B, and D have typically been specified in study protocols, albeit not as part of a 
unified estimand definition. Element C is a new requirement. Intercurrent events are those events 
that occur after randomization and alter the course of the randomized treatment during the intended 
study treatment period. Examples of such events include premature discontinuation of the 
randomized treatment, initiation of rescue therapy, or switch to an alternative therapy. Some ICEs 
may also represent a change in the subject state, e.g., death.  
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Post-randomization events can undermine randomization and compromise the evaluation of causal 
effects of the randomized treatment. Post-randomization treatment changes may confound the 
effect of the originally randomized treatment. Although the causal link between the assignment to 
a randomized treatment and the outcome may still exist, the outcome will reflect the pharmacologic 
effect of the entire realized treatment history, which may be different from that of the randomized 
treatment.  
ICH E9(R1) suggested five strategies that can be used to handle ICEs: 
 Treatment policy  
 Composite 
 While-on-treatment 
 Hypothetical 
 Principal stratification 
The strategy choice is driven by the treatment regimen that is targeted for evaluation and depends 
on the clinical context. When the treatment policy strategy is used for an ICE that marks the start 
of a new treatment, the new treatment becomes part of the evaluated treatment regimen in addition 
to the randomized treatment. Note that a “new treatment” may represent a period of no treatment, 
e.g., when the originally randomized treatment is discontinued and no alternative therapy is 
administered. The other four strategies are used when ICEs mark the start of new treatment 
elements that should not be included in the evaluated treatment regimen as they introduce 
confounding in the estimate of treatment effect, which would make it difficult or impossible to 
derive useful conclusions about causal effects of the experimental treatment in view of a specific 
study objective.  
 7 
The estimand should be defined early in the trial design process: after identifying the decision-
maker(s) and their objectives, and before estimating the required sample size, planning assessment 
schedule, and choosing analysis methods. Once the estimand is defined, the estimators (statistical 
analysis methods) should be chosen to align with the estimand. The strategies specified in the 
estimand to handle ICEs determine which data are useful for the estimand and, therefore, influence 
when and how data should be collected.  
For convenience the study development process chart from our companion paper1 is reproduced 
in Figure 1. The examples presented herein focus on step 2 of this process, defining an estimand. 
with brief comments on steps 3 and 4.   
[Figure 1. Study development process chart. PLACEHOLDER] 
 
 
 
 
Figure 1: Study development process chart 
3. Proof-of-concept trial in major depressive disorder. 
Background 
Major depressive disorder (MDD) is a common psychiatric condition with a lifetime incidence of 
approximately 15%4. The disorder ranges from mild to severe and is associated with significant 
potential morbidity and mortality, contributing to suicide and adverse impact on concomitant 
medical illnesses, interpersonal relationships, and work. The treatment objectives are to reduce 
 8 
or resolve signs and symptoms of the disease, restore psychosocial and occupational function, 
and reduce the likelihood of relapse or recurrence5. Guidelines support pharmacological therapy 
for the treatment of depression in addition to psychotherapy. Antidepressant medications include 
selective serotonin reuptake inhibitors (SSRIs), serotonin/ norepinephrine reuptake inhibitors 
(SNRIs), atypical antidepressants, serotonin-dopamine activity modulators (SDAMs), tricyclic 
antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs)6. Antidepressants in 
established classes (e.g., SSRIs, SNRIs) typically demonstrate initial benefits after 3 to 4 weeks. 
The current standard design for short-term efficacy trials in MDD are randomized, double-blind, 
placebo-controlled, parallel designs of 6 to 8 weeks’ duration7. Expectations are that patients of 
all severities will be evaluated, but that evaluation of patients with treatment-resistant depression 
(usually defined as having failed 2 or more pharmacologic therapies) will be performed 
separately. 
There are several aspects to consider for PoC trials in MDD: high rates of placebo response and 
premature discontinuation of the randomized treatment which limit the ability to distinguish an 
effective drug from placebo8,9.   
Another consideration for PoC trials (not specific to MDD) is that at this early stage of 
development, the optimum dose, dosing regimen, and/or formulation may not be known. 
Suboptimal dosing in the PoC trial could reduce treatment effects. However, knowledge gained 
from the PoC study could result in improved dosing and improved outcomes in subsequent trials.  
Trial description 
The example trial was a randomized, double-blind, placebo-controlled, parallel-group Phase 2, 
PoC trial in MDD with an 8-week treatment period in an adult outpatient population10. The primary 
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efficacy outcome was the GRID-Hamilton Depression Rating Scale (GRID-HAMD) 17-item total 
score11 at the end of the 8-week double-blind treatment period. Efficacy assessments are planned 
at baseline, and each post-baseline visit at Weeks 1-8.  
At this early stage of development in this indication, treatment regimens involving other drugs are 
not relevant. Moreover, with many drugs already on the market for MDD, new drugs are likely to 
be used in difficult-to-treat patients that have not responded to or been intolerant of other drugs, 
making assessments including rescue therapies less relevant. Therefore, no rescue therapy was to 
be made available concomitantly with the randomized treatment. If patients prematurely 
discontinued the randomized treatment (which would be considered an ICE), they were offered a 
standard-of-care therapy, which may include no pharmacological treatment depending on patient’s 
symptoms. The objective was to evaluate the experimental treatment with respect to its 
pharmacological efficacy and to assess the tolerability and adherence separately. 
Primary estimand 
We now follow the study development process presented in Section 2 for the primary objective of 
evaluating efficacy. 
1a. Identify decision-maker: The key decision-maker is the sponsor.  
1b. Define objective: The main objective is to determine whether to continue development of this 
investigational product (IP) into Phase 3 by evaluating superiority of the pharmacological effect 
of the experimental drug to placebo in treating the symptoms of MDD. 
2a. Identify possible ICEs: Actual treatment regimens that may occur in this trial in either a planned 
manner (as per the study treatment discontinuation guidelines mentioned above) or unplanned, are 
summarized in Table 1. Scenario 1 represents ideal adherence to the randomized treatment through 
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8 weeks of the double-blind period, without any ICEs. (Note: by ideal adherence we do not mean 
100% compliance, but rather continuing with the randomized treatment for the planned duration 
of 8 weeks). Treatment changes, i.e., switch to no treatment or to standard of care, represented by 
scenarios 2 and 3, respectively, are ICEs which may occur at any time during the 8-week double-
blind period. Concomitant use of other antidepressant medications is prohibited. Deaths are not 
expected during this short-term study in the enrolled subject population.   
Table 1: Anticipated treatment regimens in a PoC trial of MDD 
Scenario Treatment regimen over 8-week period 
1 Z 
2 Z→O 
3 Z→P(i) 
Z = randomized treatment; O = no treatment; P = post discontinuation of randomized treatment; 
(i) = standard of care treatment for MDD, not pre-specified by study protocol. 
 
2b. Define treatment regimen under evaluation: The treatment regimen intended for evaluation to 
address the objective stated in (1b) is the randomized treatment administered as directed for the 
planned duration of 8 weeks. The motivation for this choice is to assess the full efficacy potential, 
i.e., the pharmacologic effect, of the experimental treatment if all subjects adhere to it.  
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2c. Define estimand: The estimand is defined as follows, specifying the four elements as outlined 
in Section 2 per ICH E9(R1): 
A. The treatment effect is to be estimated for the population of adult patients with MDD as 
defined by the protocol inclusion/exclusion criteria (in the sense of delineating the 
population).  
B. Efficacy is to be measured using the primary endpoint of the change from baseline to Week 
8 of the double-blind study period in GRID-HAMD 17-item total score.  
C. All ICEs leading to changes in treatment, such as premature discontinuation of the 
randomized treatment with or without a switch to alternative therapies, will be handled by 
a hypothetical strategy to estimate what the outcome would have been at the designated 
time point if all subjects adhered to their randomized treatment through that time point.  
D. The mean of changes from baseline to Week 8 of the double-blind study period in GRID-
HAMD 17-item total score will be estimated for each treatment group and the experimental 
treatment will be compared to placebo using difference in group means. 
3a. Data useful for estimand: The GRID-HAMD 17-item data necessary for this estimand are those 
observed while adhering to the initial randomized treatment. Observations after discontinuation of 
the randomized treatment, regardless of initiation of subsequent therapies, are not useful for 
evaluation of the pharmacological effect of an 8-week study treatment regimen. Therefore, the 
data after such ICEs do not need to be collected for the purposes of this estimand. For subjects 
with ICEs, Week 8 data will not be available and the corresponding outcomes will need to be 
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estimated via statistical modeling in a manner that is consistent with the hypothetical scenario 
stated in element C of the estimand definition (see more details in step (4a) below).   
Although data post ICEs are not required for the primary estimand, it may be useful to collect these 
data for estimation of supportive estimands that can inform subsequent trials. 
3b. Patient retention strategy: Retention strategies can focus on trial conduct features to minimize 
missing data. These features go beyond our current scope and have been discussed elsewhere12.  
4a. Main estimator: An estimator aligned with the estimand is a likelihood-based repeated 
measures approach, such as mixed model for repeated-measures (MMRM)2,13. The MMRM model 
should be applied to all available data (changes from baseline in GRID-HAMD-17 total score) 
collected from all randomized subjects at scheduled assessments during adherence to randomized 
treatment, i.e., through Week 8 or the latest time point prior to an ICE. The model should typically 
include an unstructured modeling of time and within-subject correlations. The treatment contrast 
between the experimental treatment and placebo at Week 8 is the estimate of the primary estimand 
(see additional details in our companion paper on estimators2). 
4b. Missing data assumption: In this trial, some intermittently missing data may be expected due 
to subjects occasionally missing a study visit while continuing with the randomized treatment. 
Additionally, data post ICEs as described in the element C of the estimand definition are not usable 
for the primary estimand even if collected and will be treated as missing. For both types of missing 
data, the primary analysis MMRM model assumes that subjects with missing data would have 
efficacy outcomes like those in similar subjects in their treatment group who continue their 
randomized treatment through the time point at which data are missing, up to Week 8. This type 
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of assumption is referred to as Missing at Random (MAR)12. This assumption is aligned with the 
estimand and the hypothetical strategy in element C. 
4c. Sensitivity estimators: Sensitivity analysis needs to be conducted to assess the robustness of 
conclusions from the primary analysis to missing data assumptions. The key assumption in the 
primary analysis is that missing data arise from an MAR mechanism. This assumption can be 
stress-tested via a delta-adjustment tipping-point sensitivity analysis (see references14,2 for 
additional details). 
4d. Sample size: Sample size required for the primary estimand defined above is based on the 
treatment effect size expected under ideal adherence through Week 8 as well as the anticipated 
rate of ICEs. Subsequent trials may need to allow for additional margins for sensitivity analyses 
or adjust sample size for other estimands. 
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4. Confirmatory trial in severe asthma 
Background 
Asthma is a heterogeneous chronic inflammatory respiratory disease and impacts over 300 million 
people worldwide. Characterized by symptoms of wheezing, shortness of breath, chest tightness 
and/or cough, and accompanied by variable expiratory airflow limitation, asthma ranges from mild 
to severe disease15 associated with compromised quality of life and reduced survival16. Goals of 
asthma management include achieving symptom control, maintaining normal levels of activity, 
and minimizing future exacerbations to avoid long-term morbidity and mortality16. Early treatment 
increases the likelihood of improved asthma control and less additional asthma medication use17. 
In addition to addressing modifiable risk factors and non-pharmacologic approaches, subjects 
often step up pharmacologic therapy with increasing doses and potency of inhaled corticosteroids 
(ICSs), leukotriene receptor antagonists (LTRAs), theophylline, and long acting beta2-agonists 
(LABAs) based on continued symptomatology, receiving short acting beta2-agonists (SABAs) as 
needed. Those with continued symptoms may receive additional therapy with  oral corticosteroids 
(OCSs) and/or anti-immunoglobulin E (IgE) or interleukin 5 (IL-5) inhibitors16.   
In clinical trials of new add-on treatments for subjects with severe asthma uncontrolled with high-
dosage ICSs and LABAs, a placebo-controlled add-on design (standard therapy plus experimental 
drug versus standard therapy plus placebo) with a provision for a short-term rescue medication is 
the preferred approach18. Marketing approval of new medicines is typically based on the primary 
efficacy measure of clinically significant asthma exacerbations rate18. Clinically significant 
exacerbations of asthma are usually defined as a requirement for systemic corticosteroids or an 
increase of the maintenance dose of oral corticosteroids for at least three days and/or a need for an 
 15 
emergency visit, hospitalization or death due to asthma. A clinical trial of one-year duration is 
required by regulators to assess annual exacerbation rate18.  
In asthma trials of add-on therapies, the standard asthma controller background therapy consists 
of an ICS/LABA formulation. The pre-study dosage and regimen is continued throughout the study 
treatment period. Other allowed asthma controllers (e.g., long-acting muscarinic antagonists 
(LAMAs), LTRAs, OCSs) that the subject may have been taking at least 30 days prior to enrolment 
are usually allowed during the study, but typically, prior exposure to biologic therapies would not 
be permitted or would require sufficient washout. SABAs via a metered dose device are also 
typically permitted as needed for worsening asthma symptoms, i.e., for occasional short-term 
rescue use. However, a regularly scheduled or prophylactic (e.g., prior to planned exercise) use of 
SABAs in absence of asthma symptoms is typically discouraged. Other changes to treatment are 
also typically discouraged or disallowed during the study treatment period, e.g., changes to the 
subject’s background controller regimen, use of LABAs as a reliever, etc. Asthma exacerbations 
are normally treated with oral or other systemic corticosteroids according to standard practice, and 
the protocols typically outline the exacerbation treatment guidelines. Each study may include a list 
of other specific non-asthma excluded medications.  
Trial description 
For illustration purposes, we consider the SIROCCO trial19 of benralizumab. In the remainder of 
this section, we summarize the main features of this trial and the primary estimand used as the 
basis for marketing approval of benralizumab in as much as we can infer it from the study 
publication19 and publicly available regulatory marketing application review documents20, 21, 22. 
Then we discuss another estimand that may be of interest for supportive purposes. 
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The SIROCCO trial was a randomized, placebo-controlled Phase 3 study of benralizumab for 
subjects with severe asthma uncontrolled with high-dosage ICSs and LABAs. Subjects were to 
receive injections of the study drug as add-on to a stable pre-study standard-of-care therapy at 
clinical centers every 4 weeks for the duration of 48 weeks. Planned assessment times included 
the randomization visit (Week 0) and visits at 4-week intervals during the treatment period (Weeks 
4, 8, 12, …, 48). The primary endpoint was the annual asthma exacerbation rate, evaluated over 
48 weeks. The primary objective was to demonstrate efficacy in an enriched population of subjects 
with blood eosinophil counts of at least 300 cells per μL at baseline. The objective was to assess 
the effect of benralizumab as an add-on treatment. Therefore, subjects continued taking their 
background asthma controller treatments with a stable pre-study dosage and regimen during the 
study treatment period. The allowed rescue therapy, discouraged/disallowed medications, and 
management of exacerbation events in this study were similar to the typical setting of an add-on 
treatment trial for severe asthma subjects described above.  
Primary estimand 
We now follow the steps of the clinical trial design process chart from Section 2 while 
reconstructing what the primary estimand was in the SIROCCO study. 
1a. Identify decision-maker: The key decision-makers were the regulatory agencies.  
1b. Define objective: The primary objective was to determine whether to grant marketing 
authorization approval by evaluating effectiveness of the experimental drug, benralizumab, 
compared to placebo as an add-on maintenance treatment in patients with severe asthma. 
2a. Identify possible ICEs: Actual treatment regimens that may have been anticipated in the 
SIROCCO trial, occurring in either planned or unplanned manner, are summarized in Table 2. All 
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scenarios in this table, except the one in the first row, represent ICEs that occur at the time point 
when the treatment changes from the randomized treatment (Z) to either the pre-study background 
therapy only (O) or a different treatment. Using the notation in Table 2, C(i) represents a protocol-
allowed rescue therapy for short-term management of worsening asthma symptoms, whereas 
treatment changes (ii) and (iii) were discouraged or not allowed. Any of the listed treatment 
changes could occur at any point in the trial; their handling in the primary estimand did not depend 
on the timing.  
Typical study treatment completion rates in similar studies range between 80% and 85%, with 
higher rates observed in more recent confirmatory studies. The treatment completion rates in the 
SIROCCO trial were 89%, 87%, and 90% for the three treatment groups respectively19. A total of 
8% took a disallowed concomitant medication, the most common of which was regularly 
scheduled SABAs20. Withdrawals and important protocol deviations were fairly balanced across 
treatment groups22. 
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Table 2: Anticipated treatment regimens in a trial of severe asthma   
Scenario Treatment regimen over 48 weeks 
1 Z 
2 Z→O 
3 Z→C(i) 
4 Z→P(i) 
5 Z→P(ii) 
6 Z→C(ii) 
7 Z→P(iii) 
Z = randomized treatment as add-on to pre-study ICS/LABA regimen; O = background pre-
study ICS/LABA regimen only; C = concomitantly with the randomized treatment; P = post 
discontinuation of randomized treatment; (i) = SABAs for worsening asthma symptoms as 
rescue and protocol-specified treatment for exacerbation events; (ii) = changes to the subject’s 
background controller regimen, regular or prophylactic use of SABAs, treatment with short-
acting anticholinergics or with oral or injectable corticosteroids outside of managing an asthma 
exacerbation event, use of LABAs as a reliever; (iii) = alternative treatment for asthma, not pre-
specified by study protocol. 
Note: In addition to the above treatments, exacerbation events were managed as per the study-
defined treatment protocol. 
 
2b. Define treatment regimen under evaluation: The treatment regimen under evaluation was the 
randomized treatment taken for up to 48 weeks as add-on to the subject’s background pre-study 
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ICS/LABA regimen and including protocol-defined rescue therapy and treatment of exacerbation 
events, as well as including any other asthma treatments that may be administered in the course of 
the 48-week study period as per the investigator and subject decision.  
In other words, as discussed in the companion paper on estimands1, the effect of being assigned to 
one of the three study treatment groups was evaluated. 
2c. Define estimand: The primary and secondary estimands were not explicitly defined for the 
SIROCCO trials. Based on the reported methods and results19, we infer that the primary efficacy 
estimand was: 
A. The treatment effect was to be estimated for the population of adult and adolescent patients 
with severe asthma uncontrolled with high-dosage ICSs and LABAs as defined by the 
protocol inclusion/exclusion criteria (in the sense of delineating the population) who had 
blood eosinophil counts at entry of at least 300 cells per μL.  
B. Efficacy was to be measured using the primary endpoint of the number of asthma 
exacerbations experienced by a subject over the 48-week double-blind study period.  
C. All types of ICEs, including use of SABAs for worsening asthma symptoms as rescue, 
treatment of exacerbation events as specified in the study protocol, a premature 
discontinuation of the randomized treatment, and any modifications of asthma treatment 
including those that were discouraged / disallowed by study protocol but might have 
occurred as per the investigator and subject decision, were handled using the treatment 
policy strategy, i.e., included in the treatment regimen under evaluation. 
D. The annual rate of asthma exacerbation events was to be calculated for each randomized 
treatment group based on the data collected over the 48-week post-randomization period, 
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and each of the experimental treatment groups was to be compared to the placebo group 
using the event rate ratio. 
 
The ICEs corresponding to the use of SABAs for worsening asthma symptoms as rescue and 
treatment of exacerbation events are protocol-defined treatments that are part of the standard-of-
care recommended for ongoing disease management in this patient population. Based on their 
mechanism of action, and on considerable prior clinical experience, these therapies are not 
expected to produce lasting, disease-modifying effects. Apparently, a treatment policy strategy 
was applied for all ICEs. That is, no ICEs were a break from the treatment regimen under 
evaluation. Using the treatment policy approach for all ICEs seems disconnected with the trial 
design in that the protocol explicitly stipulated medications that were discouraged or not allowed, 
but the analytic approach disregarded this fact. These ICEs may have been thought as likely to 
occur in the general clinical practice in a small percentage of this patient population. Therefore, 
the overall treatment effect estimated in the presence of these ICEs was not expected to be 
significantly biased and was considered clinically relevant for evaluation of benralizumab 
effectiveness for marketing approval. 
3a. Data useful for estimand: Because the treatment policy strategy was used for all types of ICEs, 
usable data for this estimand were the exacerbation-related data over the 48-week post-
randomization period regardless of adherence to the randomized treatment. Subjects who switched 
to an alternative asthma treatment after they discontinued from the randomized treatment were 
expected to complete the remaining study visits. Subjects who had post-randomization treatment 
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changes discouraged or disallowed by the protocol were not withdrawn from the study and 
continued to be followed as planned. 
3b. Patient retention strategy: It was expected that the study withdrawal rate would be 
considerably lower than the treatment discontinuation rate due to the post-treatment 
discontinuation data collection effort21. However, the study completion rates, 90%, 89%, and 90% 
for placebo, benralizumab 30 mg Q4W, and benralizumab 30 mg Q8W treatment groups 
respectively, were only slightly higher than the treatment completion rates 89%, 87%, and 90% 
for the three treatment groups respectively19. The completion rate in the SIROCCO trial was 
greater than similar historical trials (80-85%), which could indicate a general trend in recent years 
of regulatory and sponsors emphasizing improved subject retention.  
4a. Main estimator: The SIROCCO trial analyzed the rates of exacerbation events with a negative 
binomial model for recurrent event data23 with the logarithm of the subject’s follow-up time used 
as an offset variable in the model to adjust for different follow-up times. The response variable 
was the number of exacerbation events reported by a subject over the double-blind treatment 
period. The model included covariates of treatment group, region, number of exacerbations in 
previous year, and the use of maintenance oral corticosteroids.  
4b. Missing data assumption: Although using the treatment policy strategy for all types of ICEs 
generally reduces the amount of missing data as compared to other strategies, missing data may 
nevertheless occur (as it did in the SIROCCO trial) due to subjects withdrawing from the study. 
To account for a shorter duration of follow-up of subjects who withdrew, the primary analysis 
negative binomial model should include an offset term for the logarithm of follow-up duration. 
The negative binomial model makes the assumption that missing data were MAR, i.e., that subjects 
who withdrew from the study would, taking into account their exacerbation rate up to the time of 
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withdrawal, have a similar exacerbation rate post-withdrawal to the exacerbation rate of subjects 
in the same treatment group who remained in the study (and who have similar values of baseline 
characteristics included in the model).  
4c. Sensitivity estimators:  Sensitivity analysis focusing on the assumptions about missing data can 
be performed by varying assumptions about the rates of exacerbations after early study withdrawal, 
e.g., in the SIROCCO trial it was assumed that subjects with missing data from the experimental 
arms had a greater exacerbation rate post-withdrawal than those who withdrew from the placebo 
arm21. A range of such assumptions can be considered to find a tipping point24.  
Another option for handling post study withdrawal missing data for the main or sensitivity 
estimator could be to impute these missing data based on the model estimated from subjects who 
discontinued the randomized treatment but remained in the study and have available data, as they 
can be considered as a reference group that would fit the estimand by providing clinically plausibly 
poor imputed data. However, this approach may have been impractical as the number of subjects 
in such a reference group was small (~1% of subjects).  
4d. Sample size: Some ICEs marked treatment changes that may lower the risk of exacerbation 
events. When data after such ICEs are used for the estimation of the overall treatment effect, the 
estimated treatment difference may be attenuated, and this should be taken into account in the 
sample size calculations at the trial design stage. The impact of loss of information due to missing 
data on power should also be accounted for. 
Supportive estimand 
The primary estimand provided a pragmatic assessment of effectiveness, which could be 
considered as estimating a lower limit of the experimental drug’s efficacy. A supportive estimand 
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could indicate an upper limit of efficacy, thus enabling a decision-maker to evaluate a spectrum of 
evidence. This can be achieved by estimating the treatment effect corresponding to adherence to 
randomized treatment, allowing only for the protocol-defined rescue therapy and treatment of 
exacerbation events. The benefit of the randomized treatment while taken as directed can 
subsequently be interpreted considering separate analyses of safety, tolerability, and adherence25. 
This supportive estimand would also be consistent with the stipulations of allowed and not allowed 
medications in the protocol, i.e., using the treatment policy strategy only for ICEs of the type 
“Z→C(i)” in Table 2. This approach with respect to the concomitant medications would also 
follow the recommendations in the EMA guidelines on the clinical investigation of medicinal 
products for the treatment of asthma18, which suggests that “concomitant and rescue therapy 
should be simplified where possible and documented to avoid compromising the interpretation of 
the data”. 
We now follow the trial design process chart again to define a supportive estimand. 
Steps 1a (Identify decision-maker), 1b (Define objective), and 2a (Identify possible ICEs) are 
similar to those discussed for the primary estimand, with an exception being that the objective here 
is to provide a supportive estimand for a broader evaluation of efficacy. 
2b. Define treatment regimen under evaluation: The treatment regimen under evaluation is the 
randomized treatment taken as directed for up to 48 weeks, including use of SABAs for worsening 
asthma symptoms as rescue and treatment of exacerbation events as specified in the study protocol. 
2c. Define estimand: The elements A and D for the primary endpoint of the number of exacerbation 
events would remain the same as in the case of the primary estimand, while the elements B and C 
would describe a combination of the treatment policy and while-on-treatment strategies: 
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B. Efficacy is to be measured using the primary endpoint of the number of asthma 
exacerbations reported by a subject while he/she receives the randomized treatment as 
directed, possibly with occasional uses of SABAs and management of exacerbation events 
as permitted by the protocol, up to 48-weeks of the double-blind study period. 
C1. For subjects who require SABAs as rescue treatment for worsening asthma symptoms or 
treatment of exacerbation events as specified in the study protocol, outcomes observed 
during the period of these additional treatments while continuing the randomized treatment 
as directed are included as they are consistent with the treatment regimen under evaluation. 
Therefore, the treatment policy strategy is used with respect to these types of ICEs. 
C2. For subjects who initiate any other changes to their treatment, including any asthma 
treatments or changes to the background controller therapy which are 
discouraged/disallowed by study protocol or a premature discontinuation of the 
randomized treatment, outcomes after the ICEs that mark the start of such treatment 
changes are irrelevant for evaluation of the treatment regimen of interest. A while-on-
treatment strategy will be used with respect to these ICEs. 
3a. Data useful for estimand: Data useful for this estimand are the observations collected while 
subjects adhere to the randomized treatment and take additional treatments only for rescue or 
management of exacerbation events as permitted by the protocol. All data after discontinuation of 
the randomized treatment and data after ICEs that mark the start of additional treatments that are 
discouraged or disallowed by the protocol would not be useful for this estimand and would be 
excluded from analyses.  
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Step 3b (Patient retention strategy) would not require any changes compared to what was 
discussed in the context of the primary estimand. 
4a. Main estimator: The main estimator for analysis of exacerbation rates would remain the same 
as for the primary estimand, the only difference being the data that would be included in the 
analysis as discussed in (3a). The offset term for the logarithm of the subject’s follow-up duration 
in the negative binomial model accounts for the varying length of time during which the 
exacerbations are counted for each subject. Note that this estimand does not target the treatment 
effect over the full intended study period of 48 weeks for all subjects. It aims at assessing the 
treatment effect during the period of adherence only, regardless of the duration. However, group-
level estimates may still be reported in terms of the annualized exacerbation rates for ease of 
interpretation and comparison with the primary estimand. In this case the annualized exacerbation 
rate estimates from the negative binomial model are based on the MAR assumption, but, unlike in 
the primary estimand, here the extrapolation is based exclusively on the data that reflects the event 
rates during adherence to treatment.   
4b. Missing data assumption: For the endpoint of the number of exacerbation events in the context 
of an estimand with while-on-treatment strategy, the only subjects with missing data are those who 
do not have adequate follow-up data to support determination of whether they did or did not have 
exacerbation events while receiving the treatment regimen of interest – for these subjects the 
exacerbation rate is assumed to remain constant. The while-on-treatment assumption would lead 
to far less missing data. 
4c. Sensitivity estimators: Sensitivity estimators would be similar to the slope-adjustment 
(including tipping point) methods described for the primary estimand, except that they should only 
be applied to periods of time that are on-treatment. In other words, the analytical methods could 
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be the same as in the primary estimand’s sensitivity analysis, but the data included in the analysis 
would differ, aligning with the target of the supportive estimand.    
Step 4d (Sample size) would involve similar considerations as discussed in the context of the 
primary estimand. 
5. Confirmatory trial in rheumatoid arthritis  
Background 
Rheumatoid arthritis is a systemic inflammatory autoimmune disease impacting approximately 
0.5-1% of the population. Severity ranges from mild to severe disease associated with progressive 
joint destruction, compromised quality of life, and reduced survival26,27. Remission is the optimal 
treatment goal because it is correlated with the prevention of structural damage and maintenance 
of function28,29. Early and aggressive treatment increases the likelihood of disease control30,27, 
however, remission rates are low despite significant advances in the treatment over the past two 
decades. Patients often receive one or more conventional disease-modifying antirheumatic drugs 
(cDMARDs) with methotrexate (MTX) considered the gold standard. Often, cDMARDs are used 
in combination with low-dose oral or intraarticular corticosteroids and nonsteroidal anti-
inflammatory drugs (NSAIDs). In addition, biological agents that antagonize critical inflammatory 
mediators, T cells or B cells, are used with or without concomitant cDMARDs.  
As an example for defining estimands, we consider a confirmatory trial of a biologic agent for 
MTX inadequate responder (MTX-IR) subjects. In such studies, the primary and key secondary 
endpoints are measures of symptom improvement and physical function measured at or after 12 
weeks of treatment (with earlier time points favored in recent placebo-controlled trials in order to 
limit the time of exposure to placebo). Per the FDA draft guidance for marketing approval of drug 
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products for treatment of RA31, the demonstration of efficacy should include clinical response and 
physical function using measures such as the ACR 20% response criteria (ACR20) and the Health 
Assessment Questionnaire-Disability Index (HAQ-DI), respectively. ACR20 is defined as at least 
20% improvement in the number of tender joints and swollen joints and at least 20% improvement 
in three out of the remaining five ACR core-set measures (subject pain, subject and physician 
global assessments of disease, physical functioning assessment, and acute-phase reactant). It is a 
binary (yes/no) endpoint. The HAQ-DI is a patient-reported outcome questionnaire that measures 
disease-associated disability. Although the HAQ-DI is an ordinal outcome ranging from 0 to 3, it 
is commonly analyzed as a continuous endpoint in terms of change from baseline. 
Most new biologics for MTX-IR patients are tested in combination with stable background MTX 
therapy, determined during the pre-randomization period. In some trials, the biologic may be tested 
both in combination with MTX and as monotherapy, but placebo is typically administered in 
combination with MTX. After randomization, several changes in treatment may be anticipated – 
some planned and some unplanned. Most trials in MTX-IR patients have a planned assessment of 
minimal required response to treatment, e.g., ≥20% improvement from baseline in both tender and 
swollen joint counts at a specific time point. Subjects not meeting the minimal improvement are 
offered rescue therapy for ethical reasons. Rescue may involve adjustments to background therapy, 
e.g., an increase of MTX dose or change in route of administration; addition of other cDMARDs 
such as sulfasalazine or hydroxychloroquine; increase in NSAID or prednisone dose, change in 
NSAID, or new NSAID or prednisone start; or intra-articular corticosteroid administration, or any 
combination of the preceding. Additionally, RA studies often include as rescue an “escape” (or 
“step-up”) therapy with the IP, where subjects randomized to placebo were switched to the active 
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experimental drug and subjects randomized to a lower dose of active drug were switched to a 
higher dose.  
These escape treatment switches are typically implemented in a blinded manner and triggered by 
a protocol-defined requirement for rescue, such as the minimal required response mentioned 
above. Escape therapy may confound and complicate evaluations of some estimands at time points 
after its initiation but allows for longer duration of exposures to IP, e.g., when the placebo-treated 
subject is switched to IP, to supplement the safety database. If escape therapy to a higher dose of 
IP occurs, it may also help to answer whether dose titration is a viable option to implement in 
clinical practice or not. However, historically in RA trials, the treatment effect evaluated as per the 
primary efficacy objectives typically excluded the confounding effects of escape-type rescue. 
Switching to other non-study biologic agents typically is not part of the protocol-allowed rescue 
but may occur as a result of physician’s and patient’s decision. All the above-mentioned post-
randomization treatment changes constitute ICEs and require careful consideration in the estimand 
definition. 
Trial description 
We will now discuss a hypothetical trial with design elements that resemble the historical Phase 3 
study of golimumab, GO-FORWARD32. Our example trial is a 24-week double-blinded placebo-
controlled Phase 3 trial in MTX-IR subjects evaluating an IP which is an injectable biologic agent. 
The four treatment arms are: (1) placebo injections plus MTX capsules, (2) IP injections at high 
dose as monotherapy (i.e., with placebo capsules instead of MTX), (3) IP injections at low dose 
plus MTX capsules, or (4) IP injections at high dose plus MTX capsules. Injections are to be 
administered every 4 weeks.  
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The primary efficacy evaluation is based on co-primary endpoints: ACR20 at Week 14 and change 
from baseline to Week 24 in HAQ-DI score. Although HAQ-DI can be measured at earlier time 
points, function typically follows symptomatic improvement and may continue to increase over 
time33. 
Estimand for an RA study design 1 
We first consider a study design and a primary efficacy objective mimicking the GO-FORWARD 
study as inferred from the description of methods in published material32. We define an estimand 
in that context following the trial design process chart presented in Section 2.  
1a. Identify decision-maker: The key decision-makers are the regulatory agencies.  
1b. Define objective: The primary objective was to determine whether to grant marketing 
authorization approval by evaluating effectiveness of the experimental drug compared to placebo 
at specified time points in MTX-IR patients when taken as an add-on treatment without any 
modifications of therapy post randomization.  
2a. Identify possible ICEs: Table 3 presents several scenarios of treatment sequences that may 
occur in subjects in this type of RA trial. Ideally, all subjects would stay on the randomized 
treatment (Z) through Week 24. As in the GO-FORWARD study, the need for rescue is to be 
assessed at Week 16 based on predefined criteria, and the rescue offered as part of the study is 
the escape therapy discussed above. All the treatment modifications implemented as part of this 
escape therapy will be performed in a double-blind manner. Escape therapy is denoted by “E” in 
Table 3. 
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In addition to the planned rescue, it is anticipated that the study investigators may occasionally 
modify the treatment per clinical judgment. For example, investigators could: (i) increase dose of 
MTX above the baseline dose for treatment of RA, or initiate new cDMARDs or systemic 
immunosuppressive agents, or modify treatment with oral, intravenous, or intramuscular 
corticosteroids for RA (new or dose above the baseline dose); (ii) initiate non-study biologic agents 
for RA. In our example, treatment modifications (i) may be initiated either after a permanent 
discontinuation from the study treatment (denoted by “P” in Table 3) or concomitantly with the 
randomized treatment (denoted by “C” in Table 3) as modifications in the background therapy. 
Initiation of a new non-study biologic would normally occur after the permanent discontinuation 
of the study treatment in this patient population. Some subjects may discontinue the randomized 
treatment and not initiate any new treatment before the time point of interest, i.e., remain on their 
background therapy only, as denoted by “O” in Table 3. Other subjects may initiate the escape 
therapy, but then also initiate other changes, as for example, shown in row 7 of Table 3.  We do 
not consider an exhaustive list of possibilities as to an exact timing of the treatment modifications 
– the important point is that they may occur before the time points at which efficacy needs to be 
established, e.g., Week 14 or Week 24 in our example, and therefore the changes in treatment will 
affect the interpretation of treatment effect even if all subjects are fully assessed through Week 24. 
Note that one of the two co-primary efficacy endpoints, HAQ-DI, is measured at Week 24 – i.e., 
after escape therapy could be initiated. 
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Table 3: Anticipated treatment regimens in a trial of RA in MTX-IR subjects. 
 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Treatment 
regimen over 24 
weeks 
1 Z Z Z Z Z Z Z 
2 Z Z O O O O Z→O 
3 Z Z Z E E E Z→E 
4 Z P(i) P(i) P(i) P(i) P(i) Z→P(i) 
5 Z C(i) C(i) C(i) C(i) C(i) Z→C(i) 
6 Z P(ii) P(ii) P(ii) P(ii) P(ii) Z→P(ii) 
7 Z Z Z E P(ii) P(ii) Z→E→P(ii) 
8 Z Z Z E+C(i) E+C(i) E+C(i) Z→ E+C(i) 
Z= randomized treatment as add-on to pre-study MTX regimen; O = background pre-study MTX 
treatment only; P = post discontinuation of randomized treatment; C = concomitantly with the 
randomized treatment; E = escape therapy; (i) = increased dose of MTX above the baseline dose 
for treatment of RA, new conventional disease-modifying anti-rheumatic drugs (DMARDs) or 
systemic immunosuppressive agents, treatment with oral corticosteroids for RA (new or dose 
above the baseline dose), or intravenous or intramuscular administration of corticosteroids for 
RA; (ii) = alternative biologic agents for RA, not pre-specified by study protocol. 
 
All treatment sequences in Table 3, except scenario 1 contain ICEs for which a strategy needs to 
be specified as part of the estimand definition. 
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2b. Define treatment regimen under evaluation: The treatment regimen under evaluation is the 
randomized treatment taken for up to 24 weeks without any adjustments to the background therapy 
but allowing early discontinuation due to reasons other than lack of efficacy. 
2c. Define estimand: The primary estimand that mimics the one inferred from the GO-FORWARD 
study is: 
A. The treatment effect will be estimated for the population of adult subjects with active RA 
despite MTX therapy (MTX-IR) as defined by the protocol inclusion/exclusion criteria (in 
the sense of delineating the population).  
B. Efficacy will be measured using two co-primary endpoints: ACR20 at Week 14 and change 
from baseline in the HAQ-DI score at Week 24.  
C1. For subjects who prematurely discontinue the randomized treatment for reasons other than 
lack of efficacy and do not initiate any adjustments to the background therapy, observed 
outcomes at the designated time points provide evidence compatible with the treatment 
regimen under evaluation as defined in 2b above. Therefore, the treatment policy strategy 
will be used for this ICE. 
C2. For subjects who initiate a protocol-defined escape therapy, a hypothetical strategy will be 
used to estimate what the treatment effect would have been at the designated time point if 
subjects did not receive the escape therapy and continued on their randomized treatment. 
C3. Subjects who prematurely discontinue the randomized treatment for lack of efficacy or 
initiate any treatment adjustments other than the protocol-defined escape therapy will be 
considered treatment failures at the designated time points after the start of such treatment 
changes. Therefore, the composite strategy is used for these types of ICEs. 
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D. The proportion of subjects with an ACR20 response at Week 14 will be estimated for each 
randomized treatment group, and each of the experimental treatment groups will be 
compared to the placebo group using absolute differences of proportions. Median change 
from baseline to Week 24 in HAQ-DI score will be computed for each treatment group, 
and a hypothesis of no difference between each of the experimental treatment groups and 
placebo group will be tested based on the composite outcome (as defined in part C3) 
converted to ranks, with treatment failures assigned the worst rank. An estimate of median 
treatment differences will be used to quantify the difference between each experimental 
treatment group and placebo for the HAQ-DI score. 
The treatment policy strategy for ICEs described in C1 accounts for imperfect compliance, 
including early discontinuation of study treatment in the absence of evidence (or perception) of 
lack of efficacy. A determination of the primary reason for discontinuation, however, could be 
based on subjective judgements (of patients and/or investigators) and not on formal criteria such 
as ACR20. It is, therefore, important to provide clear guidance in the protocol for determining the 
primary reason for discontinuation and close monitoring of these data during the study. 
The strategies described in C2 and C3 aim at estimating the effect of randomized treatment without 
any confounding by the effect of other medications.  
A composite strategy used for all other ICEs as described in C3 is based on interpretating all such 
events as study treatment failures and assuming that continuing with the randomized treatment 
alone would provide no chance of improvement at a later time.  
3a. Data useful for estimand: Usable data that should be collected for this estimand are 
measurements used in the ACR20 response evaluation and HAQ-DI scores at baseline and Week 
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14 and Week 24 (for the two endpoints respectively) for all subjects except those with ICEs 
described in C2 and C3 above.  
In the GO-FORWARD trial, subjects who prematurely discontinued the randomized treatment 
continued to be evaluated for safety and selected efficacy assessments for 4 months after the last 
dose of study treatment. In more recent RA trials, a typical regulatory recommendation is to 
continue study participation (with efficacy and safety evaluations) for the duration of the double-
blind period, with possibly limiting the assessments to the essential evaluations, and these 
additional data used for supportive analyses. 
3b. Patient retention strategy: Retention strategies can focus on trial features to reduce 
discontinuations from the study. Offerring adjustments to background therapy and escape therapy, 
as planned for this study, tend to help with this objective. Including an option of a simplified 
schedule of assessment after discontinuation of the randomized treatment can also improve patient 
retention in the study follow-up. Efforts should be made to minimize missing data12.  
4a. Main estimator: For analysis of ACR20 response at Week 14, standard methods for estimation 
of proportions and their differences can be used, with the hypothesis test carried out using, e.g., a 
chi-square test. For analysis of changes from baseline to Week 24 in HAQ-DI scores, a rank-based 
method, e.g., Wilcoxon rank sum test, can be used for hypothesis testing. Subjects with ICEs who 
are considered as treatment failures for this estimand are assigned the worst rank. To obtain an 
estimate of median treatment differences, e.g., a Hodges-Lehmann estimate, the treatment failure 
outcome attributed to subjects with ICEs needs to be represented by some numerical value that is 
worse than any observed value. A careful choice of such assigned value should not have material 
impact on the Hodges-Lehmann estimate, given a study of sufficient size. Other treatment 
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difference measures could also be used in conjunction with a rank-based analysis, e.g., win ratio34 
or difference of trimmed means35.  
The estimators also must accommodate the fact that subjects with ICEs, as described in C2 of the 
estimand definition, will not have observed outcomes that can be used for the estimand because 
they do not pertain to the regimen to be assessed, and need to be handled with a hypothetical 
strategy. In this study, all subjects requiring rescue as per the protocol-defined criteria are expected 
to initiate the escape rescue, and therefore no reference group with available data can be identified 
for estimating a statistical model to predict unavailable outcomes for subjects handled with the 
hypothetical approach of C2. In this case, additional estimation assumptions are necessary. In the 
GO-FORWARD trial, it was assumed that subjects who require rescue, would not improve or 
worsen if they remained on their randomized treatment between Weeks 16 and 24. This assumption 
was implemented using a Last Observation Carried Forward (LOCF) single imputation approach. 
Single imputation can lead to underestimation of variance, but an LOCF-like approach can also be 
implemented using multiple imputation36,37. 
4b. Missing data assumption: Data may be missing intermittently if a subject without any ICEs 
described in C2 and C3 of the estimand definition misses the required assessments at Week 14. 
Missing data would also arise if subjects decide to withdraw from the study overall after 
discontinuing from the randomized treatment due to reasons other than efficacy. In these cases, it 
may be reasonable to assume that the missing outcomes would be similar to those of subjects with 
similar baseline and previous post-baseline values in their treatment group (the MAR assumption). 
Multiple imputation can be used to impute these missing values. The amount of such missing data 
should be limited in a well-executed study. 
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Unobserved outcomes of subjects with ICEs as described in C2 of the estimand definition are 
assumed to be similar to their outcomes prior to escape initiation. 
4c. Sensitivity estimators. To assess sensitivity to missing data, a more extreme assumption is often 
used, where all subjects with missing/unobserved data as described above are considered as 
treatment failures. Delta adjustment/tipping point analyses can also be performed2.  
4d. Sample size: Sample size requirements should be based on assumptions that incorporate the 
likely rates of ICEs described in C1-C3 of the estimand definition above and their impact on the 
overall treatment effect. Subjects should be encouraged to continue their participation in the study 
in cases of premature discontinuation of the randomized treatment. In case of discontinuations due 
to reasons other than lack of efficacy, their data are critical, as they are used for the primary 
estimand; in other cases, their data are valuable for supportive analyses. 
Estimand for an RA study design 2 
To illustrate a broader range of possibilities, we describe a different study design and define an 
estimand in this new context. There are two key differences between the study designs 1 and 2:  
considerations for the premature discontinuations of the randomized treatment and  
implementation of a protocol-defined rescue therapy. All premature discontinuations of the 
randomized treatment will be considered treatment failures regardless of discontinuation reason 
to avoid relying on subjective judgements.The rescue therapy will now have two components: 
(1) protocol-defined adjustments to the background therapy will be made for all subjects who 
meet rescue criteria at Week 16; (2) additionally, subjects requiring rescue will be randomized at 
Week 16 to either initiate the escape therapy or not in a blinded manner.  
1a. Identify decision-maker: The key decision-makers are the regulatory agencies.  
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1b. Define objective: The primary objective is to determine whether to grant marketing 
authorization approval by evaluating effectiveness of the experimental drug compared to placebo 
at specified time points in MTX-IR patients when taken as an add-on treatment allowing for 
specific adjustments to the background therapy commonly undertaken in clinical practice (note, 
the wording in italics replaces the following wording in the RA study design 1 above: “without 
any modifications of therapy post randomization”. 
2a. Identify possible ICEs: The details of anticipated ICEs listed in Table 3 need to be refined to 
split the treatment changes mentioned under “(i)” into adjustments to the background therapy that 
will be part of the protocol-allowed rescue therapy and those that will not. The need for these 
allowed adjustments will not be considered a treatment failure. On the contrary, once these 
adjustments are made, the subject can improve meaningfully above and beyond of what is expected 
from the effect of background therapy if s/he continues the randomized treatment. For example, 
the background adjustments may allow the subject to reach the minimal required response in a 
short term but continuing with the experimental treatment might provide further benefit later as 
some subjects take more time to respond than others. The allowed adjustments will be pre-
specified in the protocol and could include an increase of MTX dose or change in route of 
administration; addition of other cDMARDs such as sulfasalazine or hydroxychloroquine; new 
NSAID or change in NSAID dose; modifications of corticosteroids use; or any combination of the 
preceding. Pre-specification enables inferences about a specific treatment regimen and an 
unambiguous interpretation and comparison with other treatments in the future.   
For the primary evaluation of efficacy, the confounding effect of treatment switching on HAQ-DI 
at Week 24 in subjects who initiate the escape therapy must be removed. We can still employ a 
hypothetical strategy for what would happen if the subject continued with the treatment regimen 
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under evaluation without the escape therapy. However, to implement this hypothetical strategy in 
a more robust manner so that it doesn’t rely solely on assumptions, subjects requiring rescue will 
be randomized in a blinded manner to either initiate escape or not, so that data can be collected 
from some subjects that actually followed the hypothesized scenario (i.e., if the subject continued 
with the treatment regimen under evaluation without the escape therapy). Note that in line with 
recent regulatory recommendations, all subjects meeting requirements for rescue will initiate 
protocol-defined changes in their background therapy regardless of whether they are randomized 
to escape or not. 
2b. Define treatment regimen under evaluation: The treatment regimen under evaluation is the 
randomized treatment taken for up to 24 weeks possibly with protocol-defined adjustments to the 
background therapy as rescue. 
2c. Define estimand: Elements A, B, and D of the estimand definition are similar to those specified 
for RA study design 1, so we focus on an alternative for element C, i.e., handling of ICEs.  
C1. For subjects who require rescue and have their background therapy adjusted as allowed per 
protocol without initiating an escape therapy, observed outcomes at the designated time 
points provide non-confounded evidence for the effect of the treatment regimen under 
evaluation. Therefore, the treatment policy strategy is used with respect to these types of 
ICEs. 
C2. For subjects who initiate a protocol-defined escape therapy, a hypothetical strategy is used 
to estimate what the treatment effect would be at the designated time point if subjects did 
not receive the escape therapy and continued on their randomized treatment with protocol-
allowed adjustments to the background therapy.  
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C3. Subjects who prematurely discontinue the randomized treatment for any reason or initiate 
any treatment adjustments other than the protocol-allowed modifications in background 
therapy are considered treatment failures at the designated time points after 
discontinuation. Therefore, the composite strategy is used for these types of ICEs. 
Part D of the estimand definition could be modified compared to the previous specification by 
choosing a binary endpoint for HAQ-DI, where a subject is defined as responder if s/he experiences 
a clinically meaningful improvement in the HAQ-DI score, defined as 0.22 or greater reduction 
from baseline38. In this case, subjects considered treatment failures as per C3 would be considered 
non-responders on this endpoint, as done for the ACR20. This alternative should be evaluated in 
terms of its impact on sample size. 
Considerations for items 3a (Data useful for estimand) and 3c (Patient retention strategy) are 
similar as in the case of the RA study design 1. 
4a. Main estimator: Analysis considerations for this estimand are similar to those discussed for 
the RA study design 1, except for handling of subjects with ICEs described in C2. Rather than an 
LOCF approach, outcomes under the hypothetical scenario (if the subject requiring rescue 
continued with the treatment regimen under evaluation without the escape therapy) can be modeled 
based on data from subjects who actually follow that scenario. Data from rescued subjects who are 
randomized not to initiate the escape therapy are used to fit a statistical multiple imputation model 
which is used to estimate hypothetical outcomes for subjects who were randomized to escape. This 
multiple imputation model should include baseline covariates and post-baseline assessments prior 
to rescue and can be implemented using reference-based imputation2.  
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4b. Missing data assumption: Considerations for this estimand are similar to those for the estimand 
of the RA study design 1, except for the assumption used with the hypothetical strategy. Subjects 
with ICEs described in C2 are assumed to have similar efficacy outcomes as subjects in their 
treatment group who also met conditions for rescue therapy and had their background therapy 
adjusted in the protocol-defined manner without receiving the escape therapy.  
4c. Sensitivity estimators. Similar sensitivity analyses as mentioned for the RA study design 1 can 
be used. 
Considerations for item 4d (Sample size) are similar as in the case of the RA study design 1. 
Discussion 
This paper illustrated examples of defining estimands consistent with the concepts outlined in ICH 
E9(R1) and discussed in our companion papers on estimands1 and estimators2. The three example 
indications illustrated a variety of ICEs that can be anticipated in each setting as well as strategies 
that can be used to handle them consistently with study objectives and the clinical context. The 
estimands chosen for these examples are not the only acceptable choices for their respective 
scenarios. As previously stated, the intent was to illustrate the process and key concepts rather than 
focus on justification of specific choices.  
Emphasis was placed on following the study design process chart in Section 2. Following the steps 
outlined in that process, a development team should arrive at a suitable estimand without need for 
iterative revisions of the study design to achieve alignment between objectives and planned 
inferences. ICH E9(R1) emphasized the importance of defining the estimands before choosing 
suitable estimators and of defining estimands that are not overburdened by statistical details so that 
team members from all backgrounds can understand and contribute to the estimand definition. Our 
 41 
examples have illustrated that this is feasible and promotes a thoughtful consideration of the 
clinical context and decision-making objectives, which is especially important in complex settings 
where many types of ICEs can be anticipated. Nevertheless, in some instances iterative revisions 
to study design may be required. For example, when sample size requirements are established and 
statistical power is evaluated for suitable estimators, it may become evident that alternative 
strategies for handling ICEs are required to ensure the study is feasible in terms of patient 
recruitment, timelines, and budget. Sample size calculations in this framework need to take 
account of various factors related to strategies chosen to handle different types of ICEs, which may 
require considering a range of assumptions and necessitate simulations. 
It is advisable to follow the study design process chart for each objective that is envisaged for the 
trial. For example, in the companion paper1, we discussed considerations for safety estimands and 
estimands related to secondary efficacy parameters such as health-related quality of life, which 
may require different approaches than the primary efficacy estimand. Using the process for each 
major objective ensures that the design and data collection are adequate for all trial needs. 
It is also advisable to verify the design considerations with respect to different stakeholders. For 
example, confirmatory trials provide the basis for the marketing approval and are also used by 
payers for Health Technology Assessment. The latter may be based primarily on considerations of 
effectiveness of prescribing/buying a therapy regardless of subsequent patterns of adherence 
(although an assumption of similarity between adherence patterns in the clinical trial and in 
practice must be made). The regulators, on the other hand, may be more interested in the 
risk/benefit of taking a specific experimental therapy rather than in the effect of being randomized 
to it. Patients and physicians may be interested in both aspects, although for these stakeholders the 
main consideration for initiating a new treatment typically is about what can be expected if it is 
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taken as prescribed. To address various perspectives and priorities, it would be valuable to   
formulate several supporting estimands for a trial, where the estimands employ different strategies 
to deal with the same ICEs in alignment with the stakeholders’ primary objectives. To aid in 
interpretation and comparison of the results under different estimands, the use of advanced 
visualization techniques is advisable. 
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